BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 33186181)

  • 1. Adrenocortical carcinoma: current treatment options.
    De Filpo G; Mannelli M; Canu L
    Curr Opin Oncol; 2021 Jan; 33(1):16-22. PubMed ID: 33186181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conventional chemotherapy and emerging targeted therapy for advanced adrenocortical carcinoma.
    Xu YZ; Zhu Y
    Anticancer Agents Med Chem; 2013 Feb; 13(2):248-53. PubMed ID: 22934700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenocortical Carcinoma: Role of Adjuvant and Neoadjuvant Therapy.
    Kenney L; Hughes M
    Surg Oncol Clin N Am; 2023 Apr; 32(2):279-287. PubMed ID: 36925185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New perspectives for mitotane treatment of adrenocortical carcinoma.
    Puglisi S; Calabrese A; Basile V; Pia A; Reimondo G; Perotti P; Terzolo M
    Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101415. PubMed ID: 32179008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.
    Sperone P; Ferrero A; Daffara F; Priola A; Zaggia B; Volante M; Santini D; Vincenzi B; Badalamenti G; Intrivici C; Del Buono S; De Francia S; Kalomirakis E; Ratti R; Angeli A; Dogliotti L; Papotti M; Terzolo M; Berruti A
    Endocr Relat Cancer; 2010 Jun; 17(2):445-53. PubMed ID: 20410174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adrenocortical carcinomas: therapeutic advances in 2011].
    Grunenwald S; Caron P
    Ann Endocrinol (Paris); 2011 Oct; 72 Suppl 1():S8-S14. PubMed ID: 22008276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update in adrenocortical carcinoma.
    Fassnacht M; Kroiss M; Allolio B
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Three Cases of Advanced or Recurrent Adrenocortical Carcinoma Patients Treated with Etoposide, Doxorubicin and Cisplatin plus Mitotane].
    Sasaki S
    Gan To Kagaku Ryoho; 2018 Jan; 45(1):67-70. PubMed ID: 29362311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors.
    Henning JEK; Deutschbein T; Altieri B; Steinhauer S; Kircher S; Sbiera S; Wild V; Schlötelburg W; Kroiss M; Perotti P; Rosenwald A; Berruti A; Fassnacht M; Ronchi CL
    J Clin Endocrinol Metab; 2017 Nov; 102(11):4323-4332. PubMed ID: 29092062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
    Postlewait LM; Ethun CG; Tran TB; Prescott JD; Pawlik TM; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Staley CA; Poultsides GA; Maithel SK
    J Am Coll Surg; 2016 Apr; 222(4):480-90. PubMed ID: 26775162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Status and Future Targeted Therapy in Adrenocortical Cancer.
    Alyateem G; Nilubol N
    Front Endocrinol (Lausanne); 2021; 12():613248. PubMed ID: 33732213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy.
    Grisanti S; Cosentini D; Laganà M; Morandi A; Lazzari B; Ferrari L; Volta AD; Ambrosini R; Ferrari VD; Sigala S; Berruti A
    Front Endocrinol (Lausanne); 2021; 12():624102. PubMed ID: 33716976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.
    Jung S; Nagy Z; Fassnacht M; Zambetti G; Weiss M; Reincke M; Igaz P; Beuschlein F; Hantel C
    Endocr Relat Cancer; 2016 Oct; 23(10):825-37. PubMed ID: 27550961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
    Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs for adrenocortical carcinoma.
    Berruti A; Ferrero A; Sperone P; Daffara F; Reimondo G; Papotti M; Dogliotti L; Angeli A; Terzolo M
    Expert Opin Emerg Drugs; 2008 Sep; 13(3):497-509. PubMed ID: 18764725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission].
    Ueda S; Nakane K; Namiki S; Takeuchi Y; Kawase M; Takeuchi S; Kawase K; Nakai C; Kato D; Takai M; Iinuma K; Tsuchiya T; Miyazaki T; Koie T
    Hinyokika Kiyo; 2022 May; 68(5):139-143. PubMed ID: 35748231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine.
    Quinkler M; Hahner S; Wortmann S; Johanssen S; Adam P; Ritter C; Strasburger C; Allolio B; Fassnacht M
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2057-62. PubMed ID: 18334586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study.
    Debets P; Dreijerink KMA; Engelsman A; Dahele M; Haak HR; Steenaard RV; Kapiteijn E; Corssmit E; Menke-van der Houven van Oordt CW
    Eur J Cancer; 2024 Jan; 196():113424. PubMed ID: 37977106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitotane With or Without Cisplatin and Etoposide for Patients with a High Risk of Recurrence in Stages 1-3 Adrenocortical Cancer After Surgery.
    Sarvestani AL; Gregory SN; Teke ME; Terzolo M; Berruti A; Hernandez JM; Habra MA
    Ann Surg Oncol; 2023 Feb; 30(2):680-682. PubMed ID: 36305989
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.